Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

6014 - Impact of FLT3-ITD mutation on post-transplant outcome of adult AML is modified by the concomitant NPM1 mutation and pre-transplant remission status: A report from Taiwan Bone Marrow Transplant Registry (TBMTR)


28 Sep 2019


Poster Display session 1


Tumour Site



Su-peng Yeh


Annals of Oncology (2019) 30 (suppl_5): v435-v448. 10.1093/annonc/mdz251


S. Yeh

Author affiliations

  • Hematology And Oncology, China Medical University Hospital, 40861 - Taichung/TW


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 6014


The impact of FLT3ITDmut on post-transplant outcome of adult AML remains controversial. A decreased leukemia-free survival (LFS) after allogeneic hematopoietic stem cell transplantation (HSCT) for adult AML in complete remission (CR) was observed in EBMT analysis but not CIBMTR. The impact of FLT3ITDmut on AML patients in later disease stage, as well as the influence of concurrent NPM1 mutation on post-transplant outcome, is less well studied.


In this study, only adults aged ≥ 18 years with a diagnosis of de novo AML who received allogeneic peripheral blood stem cell transplantation and with known FLT3ITD and NPM1 status in the registry were included. Kaplan-Meier estimates were used to calculate LFS and overall survival (OS). Multivariate analyses for LFS and OS were performed using Cox proportional hazards model.


For patients who received transplant in CR1, the 2 year LFS, OS, and relapse incidence (RI) were 33.1%, 48.7%, and 56%, respectively, for patients of FLT3ITDmutNPM1wt, which are much inferior to patients of FLT3ITDmutNPM1mut (74.3%, 77.8%, and 25.7%, respectively) and patients of FLT3ITDwt (53.5%, 71%, and 37.3%, respectively). In multivariate analysis, patients of FLT3ITDmutNPM1wt, but not patients of FLT3ITDmutNPM1mut, were associated with significant poor LFS (HR 2.672, p = 0.007) and OS (HR 2.439, p = 0.038) compared with patients of FLT3ITDwt. For patients who received transplant after CR1, FLT3ITDmut was associated with significant poor LFS (HR 1.775, p = 0.013) and OS (HR 1.716, p = 0.028) compared with patients of FLT3ITDwt. NPM1 mutation dose not influence the outcome.


For patients in CR1, the impact of FLT3ITD is markedly modified by NPM1 status. The post-transplant outcome remains poor for patients of FLT3ITDmutNPM1wt and highlights the need for a novel approach (such as maintenance FLT3ITD inhibitor after transplant). For patients after CR1, the post-transplant outcome is very poor for patients of FLT3ITDmut and is independent of NPM1 status.

Clinical trial identification

Editorial acknowledgement

The author thanks all the centers participating in the TBMTR. The report is on behalf of the Taiwan society of blood and bone marrow transplantation.

Legal entity responsible for the study

The author.


Has not received any funding.


The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.